Debts
€848,136 82% of the balance sheet
Financial debts 48%Suppliers 34%Other 18%
Of this, €514,864 falls due within a year.
SOBEGAPHARMA
Lifetime
17 annual accounts with figures on one time axispeak €287,846 (2015)
€183,099▼ 15.8%
lowest -€45,293 (2012)
€24,247▲ 0.2%
peak €187,268 (2025)
€187,268▲ 14.9%
€848,136▼ 7.6%
peak 2.1 FTE (2016)
0.8 FTEunchanged
Board1 name since 2023
1 directorMAESEN Bertrand Gabriel André Ghislain
Documentsfilings and deeds
01-02-20261 day late
2025financial year
Gross margin from €217,585 to €183,099Equity from €163,021 to €187,268
Key points
from the 2025 annual accountsFilings
17 annual accounts since 2009
Nine of the last ten came late. The 2022 accounts came latest: 28 days after the end of the period.
Position in the sector
€187,268
Less equity than 85% of companies in pharmaceuticals. Sector median €4.9m · 95 companies.
Checked score
89
Excellent
Financially stronger than 51% of micro companies in pharmaceuticals (NACE 21)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
0.2% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.4% across 152 companies (NACE 21, micro).
About 2 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.5%
01-2025: 0.7%▲ +0.2 percentage points vs 12-2024
02-2025: 1.0%▲ +0.3 percentage points vs 01-2025highest value
03-2025: 0.2%▼ -0.8 percentage points vs 02-2025
04-2025: 0.2%● unchanged vs 03-2025
05-2025: 0.2%● unchanged vs 04-2025
06-2025: 0.2%● unchanged vs 05-2025
07-2025: 0.2%● unchanged vs 06-2025
08-2025: 0.2%● unchanged vs 07-2025
09-2025: 0.2%● unchanged vs 08-2025
10-2025: 0.2%● unchanged vs 09-2025
11-2025: 0.2%● unchanged vs 10-2025
12-2025: 0.3%▲ +0.1 percentage points vs 11-2025
01-2026: 0.4%▲ +0.1 percentage points vs 12-2025
02-2026: 0.7%▲ +0.3 percentage points vs 01-2026
03-2026: 0.2%▼ -0.5 percentage points vs 02-2026lowest value
04-2026: 0.2%● unchanged vs 03-2026lowest value
05-2026: 0.2%● unchanged vs 04-2026lowest value
06-2026: 0.2%● unchanged vs 05-2026lowest value
07-2026: 0.2%● unchanged vs 06-2026lowest value
08-2026: 0.2%● unchanged vs 07-2026
09-2026: 0.2%● unchanged vs 08-2026
10-2026: 0.2%● unchanged vs 09-2026
11-2026: 0.2%● unchanged vs 10-2026
Financial strengthAverage
Score breakdown
raises risk
Equity €187,268 (18.1% of total assets)
lowers risk
Size: 0.8 FTE, total assets €1.0m
Founded in 2008
Figures for financial year 2025 (filed on 04-02-2026)
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 21, micro). It does better than 41% of them on solvency, 34% on liquidity, 60% on profitability and 69% on growth.
The bankruptcy probability was computed on 09-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 30-06-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 4,508 companies had the same profile as SOBEGAPHARMA has now. Each dot stands for 12 companies, two years later.
96.9%
were still trading
1.6%
stopped another way
1.4%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
That fits the bankruptcy probability of SOBEGAPHARMA itself: 0.2% within 12 months.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 4,508 companies, not a prediction for SOBEGAPHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €16,000 on 30-day terms is acceptable
Liquidity is tight, with a current ratio of 1.14 (1.04 in 2024), below the usual 1.5. Short-term debt is 49.7% and cash 10.5% of total assets. 81.9% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Six signals.
lowers riskraises risk
raises risk · Weak solvency compared with the sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 19% of 95 sector peers (2025).
NBB · sector comparisonPosition among 95 sector peers
Solvency
better than 19%
← weakest
strongest →
raises risk · 2025 accounts filed 1 day late
The financial year that closed on 30-06-2025 was due by 31-01-2026 and was filed on 01-02-2026, 1 day later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.
NBB · 10 filingsDeviation from the deadline
2025
1 day late
2024
17 days late
2023
14 days late
2022
28 days late
2021
3 days late
2020
13 days late
2019
21 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 14 days after the deadline. In the sector (NACE 21), the median for financial year 2024 was 9 days before the deadline, and 32% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The financial year that closed on 30-06-2026 is due by 31-01-2027. Nothing is late today. The company usually files around 14 February (5 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
30-06-2026 year end09-11-2026 today31-01-2027 deadline
Board and ownership
- ANDRE FOURMYannual accounts 30-06-2021
- BERTRAND MAESENannual accounts 30-06-2021
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0898114684
Amendment of the articles · Legal-form change · Resignations & appointments
Change of role: MAESEN Bertrand Gabriel André Ghislain, from manager to director · General meeting of 07-12-2023 · Gazette deed
First establishment
Sobegapharma., Rue des Quatre Fils Aymon 2, Mons
Incorporation
published on 04-06-2008 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| SOBEGAPHARMA Mons | €1.0m | €183,099 | 18.1% | 0.8 |
| GRNR Invest Zemst | €2.3m | €128,921 | 49.8% | 0 |
| PHARMACIE DES PAGODES Genappe | €0.4m | €152,066 | 3.0% | 1.6 |
| Pharmacie BIHAIN Trois-Ponts | €0.6m | €168,122 | 15.5% | 0.7 |
| D2S Pharma Oudenaarde | €0.6m | €129,195 | 72.9% | 0.5 |
| PHARMACIE DE GIVRY Quévy | €1.3m | €487,695 | 37.4% | 4.4 |
| Dokterspraktijk Marten Geyskens Scherpenheuvel-Zichem | €2.6m | €743,980 | 46.5% | 2.2 |
These companies have the same main activity as SOBEGAPHARMA: manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21100). They are comparable in size and age: total assets between €383,000 and €2.6m, founded between 2005 and 2014.
Official details
Source: KBO- Status
- Active since 15-05-2008Normal situation
- Activity
- Manufacture of basic pharmaceutical products and pharmaceutical preparationsNACE 21100and 3 others
- Establishment unit
- 2.171.131.4027000 Mons, since 12-06-2008
- Financial year end
- 30 June
- Peppol
- Reachable since 30-12-2025
Annual accounts to 30-06-2025
- ≈ €470,000estimated
- €1.0m▼ 4.2%
- Employeeson 30-06-2025
- 1=
- Filing
- Filed on 01-02-2026
Insights on SOBEGAPHARMA
SOBEGAPHARMA has been active since 2008 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €187,268 and a net result of €24,247.
Equity has been growing by about 26% per year since 2019. Its solvency ranks better than 19% of 95 sector peers (NACE 21, financial year 2025).
The computed 12-month bankruptcy probability is 0.2% (very low).
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about SOBEGAPHARMA
- What is the company number of SOBEGAPHARMA?
- The company number of SOBEGAPHARMA is 0898.114.684. The VAT number is the same number with BE in front: BE 0898.114.684.
- Where is SOBEGAPHARMA based?
- The registered office is at Rue des Quatre Fils Aymon 2, 7000 Mons.Company details
- What does SOBEGAPHARMA do?
- According to the KBO register, the main activity is manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21100).
- What is the legal form of SOBEGAPHARMA?
- SOBEGAPHARMA is a private limited company (BV).
- When was SOBEGAPHARMA founded?
- SOBEGAPHARMA was founded on 15-05-2008.
- Is SOBEGAPHARMA still active?
- Yes, SOBEGAPHARMA is an active enterprise in the KBO register.
- How many employees does SOBEGAPHARMA have?
- SOBEGAPHARMA had an average of 0.8 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- What is the turnover of SOBEGAPHARMA?
- The turnover in financial year 2025 is ≈ €470,000. This figure is estimated from the gross margin of €183,099 and 1,647 comparable companies of the same size. It probably lies between €280,000 and €870,000. It is a rough estimate.
- Is SOBEGAPHARMA profitable?
- In financial year 2025, SOBEGAPHARMA made a profit of €24,247.
- Where can I find the annual accounts of SOBEGAPHARMA?
- SOBEGAPHARMA filed 17 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of SOBEGAPHARMA due?
- SOBEGAPHARMA must file the annual accounts for financial year 2026 by 31-01-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.